Transaction in Own Shares

Fidelity Emerging Markets Limited repurchased and cancelled 16,114 ordinary shares on 26 January 2026 at an average price of 1,166 GBp per share. Following the transaction issued share capital stands at 52,493,583, treasury shares at 9,025,940 and total voting rights at 43,467,644; the cancellation slightly reduces the voting denominator for FCA DTR calculations but is immaterial to overall equity valuation.

Analysis

Market structure: The repurchase (16,114 shares at 1,166p) is economically immaterial (~0.03% of issued capital) but signals management preference for capital returns over dividends or immediate asset growth, benefiting long-term holders via marginal supply reduction and potential discount compression. Direct winners are existing shareholders and buy-and-hold closed‑end trust investors; marginal losers include short sellers and passive EM ETF holders who won’t capture discount tightening. Cross-asset impact is negligible short-term; larger program continuation would modestly support GBP‑listed trust equity vs. EM equities and slightly tighten synthetic financing in convertible/loan markets.

Risk assessment: Tail risks include a shift in buyback funding (forced asset sales) that depresses NAV, regulatory constraints on buybacks in the UK, or EM FX shocks that erode underlying NAV by >5% in a month. Immediate (days) effect is likely a micro bump; short-term (weeks–months) depends on whether buybacks become a program (threshold: cumulative >0.5% of issued shares); long-term (quarters) outcome tracks EM performance and GBP/USD moves. Hidden dependency: buybacks funded by treasury cash vs. portfolio disposals—monitor asset disposals and NAV changes as the decisive second‑order effect. Key catalysts: subsequent repurchase notices, monthly NAV reports, and EM macro shocks (China, Fed hikes).

Trade implications: Direct play is selective long exposure to the trust to capture discount tightening; size positions small (1–3% NAV) until management confirms repeatable program. Relative-value: long the closed‑end trust versus short EM index ETF (e.g., EEM) to isolate discount compression vs. EM beta. Options: use 1–3 month call spreads (1200/1500p) for convex exposure or sell 3‑month covered calls at ~1300p to monetize expected low-volatility sideways move. Entry: within 5 trading days; exit: on 6–12% price gain or on catalyst change (buyback funding shift or >2% NAV drag in 30 days).

Contrarian angle: The market likely underestimates signalling value—small repurchase is a trial balloon; if management scales to 0.5–1.0% of issued capital over 3–6 months the price impact can be non‑linear (multi‑percent discount compression). Conversely, consensus may overlook downside if buybacks are financed by realizing illiquid or underperforming EM assets—this would produce a permanent NAV haircut. Historical parallels: closed‑end trusts that announced sustained buybacks saw 3–8% alpha vs peers over 6 months; absence of a program ramp argues for cautious, size‑limited exposure.

Key Decisions for Investors

• Establish a 1.5% position in Fidelity Emerging Markets Limited (LSE:FEM) within 5 trading days, target +8% price appreciation over 3 months (discount compression), set stop-loss at -6% from entry; increase to 3–4% only if cumulative buybacks >0.5% of issued share capital within 6 months.
• Implement a 1% long FEM / 1% short iShares MSCI Emerging Markets ETF (NYSE:EEM) pair for 3 months to capture potential discount tightening vs EM beta; close the pair if net divergence compresses to <1% for two consecutive weeks or if EM spot returns exceed -/+5% in 30 days.
• If long FEM, sell 3‑month covered calls at ~1300p strike to generate ~income while capping upside; if seeking leveraged exposure without owning shares, buy a 3‑month 1200/1500p call spread (cost-limited) to capture upside from further buybacks or NAV recovery.
• Require monitoring triggers: escalate size only if management announces cumulative repurchases >0.5% of issued capital within 90–180 days, and liquidate or cut exposure if NAV falls >2% month-over-month coincident with buyback-funded asset sales.